Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series
SAN DIEGO , Sept. 14, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih , M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday,
View HTML
Toggle Summary Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
     Combined sparsentan treatment group experienced 44.8 percent reduction of proteinuria, more than double the reduction of irbesartan; achieves statistical significance in primary efficacy endpoint Preliminary safety findings show sparsentan was generally safe and well-tolerated Conference call
View HTML
Toggle Summary Retrophin Appoints Neil McFarlane Chief Operating Officer
SAN DIEGO , Aug. 15, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Neil McFarlane has been appointed chief operating officer. In this newly created position, Mr. McFarlane will help guide the Company's daily operations with principal responsibility for commercial
View HTML
Toggle Summary Retrophin Reports Second Quarter 2016 Financial Results
Second quarter revenues increased 38 percent year-over-year Sparsentan top-line data expected in third quarter of 2016 RE-024 efficacy trial expected to initiate in second half of 2016 SAN DIEGO , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its second quarter 2016
View HTML
Toggle Summary Retrophin to Report Second Quarter 2016 Financial Results
SAN DIEGO , July 21, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2016 financial results on Thursday, August 4, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Appoints Roy D. Baynes, M.D., Ph.D., to Board of Directors
SAN DIEGO , July 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc.  (NASDAQ:RTRX) today announced the appointment of Roy D. Baynes , M.D., Ph.D., to its Board of Directors, effective immediately. Dr. Baynes currently serves as senior vice president of Global Clinical Development at Merck Research
View HTML
Toggle Summary Retrophin Announces New Data from Physician-Initiated Treatment with RE-024 at the 20th International Congress of Parkinson's Disease and Movement Disorders
RE-024 treatment associated with clinically meaningful improvements in two PKAN patients
View HTML
Toggle Summary Retrophin Acquires Liquid Formulation of Ursodeoxycholic Acid
U.S. filing for primary biliary cholangitis indication anticipated in 2017
View HTML
Toggle Summary Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO , May 26, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc.  (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the following upcoming investor conferences: Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9, 2016 at 2:30 p.m.
View HTML
Toggle Summary Retrophin Reports First Quarter 2016 Financial Results
First quarter revenues increased 67 percent year-over-year Enrollment of the Phase 2 DUET study of sparsentan completed; top-line results expected third quarter 2016 SAN DIEGO , May 03, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its first quarter 2016 financial results.
View HTML